These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 35304396

  • 1. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
    Akiyoshi T, Shinozaki E, Taguchi S, Chino A, Hiratsuka M, Tominaga T, Nonaka T, Toda S, Matoba S, Matsui S, Okabayashi K, Mukai T, Hiyoshi Y, Yamaguchi T, Nagasaki T, Yamaguchi K, Ueno M, Kuroyanagi H, Fukunaga Y, Ishizuka N, Konishi T, for NOMINATE Collaborative Group.
    BMJ Open; 2022 Mar 18; 12(3):e055140. PubMed ID: 35304396
    [Abstract] [Full Text] [Related]

  • 2. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, Weiser MR, Guillem JG, Paty PB, Avila K, Garcia-Aguilar J, Rectal Cancer Consortium.
    BMC Cancer; 2015 Oct 23; 15():767. PubMed ID: 26497495
    [Abstract] [Full Text] [Related]

  • 3. Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.
    Alvarez JA, Shi Q, Dasari A, Garcia-Aguilar J, Sanoff H, George TJ, Hong T, Yothers G, Philip P, Nelson G, Al Baghdadi T, Alese OB, Zambare W, Omer D, Verheij FS, Bercz A, Kim MJ, Buckley J, Williams H, George M, Garcia R, Gallagher P, O'Reilly EM, Meyerhardt JA, Crawley J, Shergill A, Horvat N, Romesser PB, Hall W, Smith JJ.
    BMC Cancer; 2024 Jul 26; 24(1):901. PubMed ID: 39060961
    [Abstract] [Full Text] [Related]

  • 4. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S, Wang X, Zhuang Y, Bai S, Wu X, Ye Y, Luo H, Yu H, Wang Q, Chang H, Zeng Z, Cai P, Pan Z, Gao Y, Chen G, Xiao W.
    Cancer Med; 2023 Jun 26; 12(12):13352-13360. PubMed ID: 37156624
    [Abstract] [Full Text] [Related]

  • 5. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y, Huang SH, Chi P, Wang XJ, Lin HM, Lu XR, Ye DX, Lin Y, Deng Y.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar 25; 23(3):281-288. PubMed ID: 32192308
    [Abstract] [Full Text] [Related]

  • 6. Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial.
    Kim MJ, Lee DW, Kang HC, Park JW, Ryoo SB, Han SW, Kim KS, Chie EK, Oh JH, Jeong WK, Kim BH, Nam EM, Jeong SY.
    BMC Cancer; 2023 Aug 08; 23(1):734. PubMed ID: 37553666
    [Abstract] [Full Text] [Related]

  • 7. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW, Kang BM, Kim IY, Kim JY, Park SJ, Park WC, Bae KB, Bae BN, Baek SK, Baik SH, Son GM, Lee YS, Lee SH.
    BMC Cancer; 2018 May 08; 18(1):538. PubMed ID: 29739356
    [Abstract] [Full Text] [Related]

  • 8. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL, Meng WJ, Shu P, Deng XB, Wu B, Jiang D, Zhuang H, Shen YL, Zhou ZG, Wang ZQ, Wang X.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr 25; 22(4):349-356. PubMed ID: 31054549
    [Abstract] [Full Text] [Related]

  • 9. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
    Wang YQ, Shen LJ, Wan JF, Zhang H, Wang Y, Wu X, Wang JW, Wang RJ, Sun YQ, Tong T, Huang D, Wang L, Sheng WQ, Zhang X, Cai GX, Xu Y, Cai SJ, Zhang Z, Xia F.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May 25; 26(5):448-458. PubMed ID: 37217353
    [Abstract] [Full Text] [Related]

  • 10. Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol.
    Huang W, Huang P, Guo H, Huang Z, Wei M, Guo J, Lin C, Li Y, Luo B, Lin J, Wang L.
    BMJ Open; 2023 Oct 05; 13(10):e075023. PubMed ID: 37798027
    [Abstract] [Full Text] [Related]

  • 11. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH).
    Wang Y, Shen L, Wan J, Zhang H, Wu R, Wang J, Wang Y, Xu Y, Cai S, Zhang Z, Xia F.
    BMC Cancer; 2022 Mar 15; 22(1):274. PubMed ID: 35291966
    [Abstract] [Full Text] [Related]

  • 12. ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.
    Alvarez J, Shi Q, Dasari A, Garcia-Aguilar J, Sanoff H, George TJ, Hong TS, Yothers G, Philip PA, Nelson GD, Al Baghdadi T, Alese O, Zambare W, Omer DM, Verheij FS, Buckley J, Williams H, George M, Garcia R, O'Reilly EM, Meyerhardt JA, Shergill A, Horvat N, Romesser PB, Hall WA, Smith JJ.
    medRxiv; 2024 Apr 27. PubMed ID: 38712176
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
    van den Berg K, Schaap DP, Voogt ELK, Buffart TE, Verheul HMW, de Groot JWB, Verhoef C, Melenhorst J, Roodhart JML, de Wilt JHW, van Westreenen HL, Aalbers AGJ, van 't Veer M, Marijnen CAM, Vincent J, Simkens LHJ, Peters NAJB, Berbée M, Werter IM, Snaebjornsson P, Peulen HMU, van Lijnschoten IG, Roef MJ, Nieuwenhuijzen GAP, Bloemen JG, Willems JMWE, Creemers GJM, Nederend J, Rutten HJT, Burger JWA.
    BMC Cancer; 2022 Sep 06; 22(1):957. PubMed ID: 36068495
    [Abstract] [Full Text] [Related]

  • 14. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
    Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP, RAPIDO collaborative investigators.
    Lancet Oncol; 2021 Jan 06; 22(1):29-42. PubMed ID: 33301740
    [Abstract] [Full Text] [Related]

  • 15. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
    Wang L, Zhang XY, Zhao YM, Li SJ, Li ZW, Sun YS, Wang WH, Wu AW, Rectal Cancer Cooperative Group of Peking University Cancer Hospital.
    Ann Surg; 2023 Apr 01; 277(4):647-654. PubMed ID: 35766394
    [Abstract] [Full Text] [Related]

  • 16. Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.
    Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M, Bacchus investigators.
    BMC Cancer; 2015 Oct 23; 15():764. PubMed ID: 26493588
    [Abstract] [Full Text] [Related]

  • 17. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW, Zhang KN, Wang C, Han JG, Ma HC, Wei GH, Yang Y, Wang ZJ.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar 25; 23(3):274-280. PubMed ID: 32192307
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
    Huang CY, Bai MH, Shen JW, Sun QQ, Feng YR, Chen QP, Mao W, Ju HX, Zhu J.
    BMC Cancer; 2024 Jan 10; 24(1):57. PubMed ID: 38200410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.